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24 The Journal of Thoracic and Cardiobjectives: The objectives of this study were to develop a risk-adjusted model to
stimate individual postoperative costs after major lung resection and to use it for
nternal economic audit.
ethods: Variable and fixed hospital costs were collected for 679 consecutive
atients who underwent major lung resection from January 2000 through October
006 at our unit. Several preoperative variables were used to develop a risk-adjusted
conometric model from all patients operated on during the period 2000 through
003 by a stepwise multiple regression analysis (validated by bootstrap). The model
as then used to estimate the postoperative costs in the patients operated on during
he 3 subsequent periods (years 2004, 2005, and 2006). Observed and predicted
osts were then compared within each period by the Wilcoxon signed rank test.
esults: Multiple regression and bootstrap analysis yielded the following model
redicting postoperative cost: 11,078  1340.3X (age  70 years)  1927.8X
ardiac comorbidity  95X ppoFEV1%. No differences between predicted and
bserved costs were noted in the first 2 periods analyzed (year 2004, $6188.40 vs
6241.40, P  .3; year 2005, $6308.60 vs $6483.60, P  .4), whereas in the most
ecent period (2006) observed costs were significantly lower than the predicted ones
$3457.30 vs $6162.70, P  .0001).
onclusions: Greater precision in predicting outcome and costs after therapy may
ssist clinicians in the optimization of clinical pathways and allocation of resources.
ur economic model may be used as a methodologic template for economic audit
n our specialty and complement more traditional outcome measures in the assess-
ent of performance.
s a result of an increasing cost awareness and a relative scarcity of
resources, it has become important to optimize and quality-assure medical
interventions.
Ideally, the clinical care team would select and implement the strategy of care
hat maximizes patient outcomes without wasting scarce resources. Thus, both
nformation regarding the patient’s medical outcomes and the estimated relative
esource use associated with a set of alternative therapies become important con-
iderations in the clinical team’s decision-making process.
In this regard, the identification of candidates for lung surgery at increased risk
f higher costs may assist in the allocation of limited resources and in the economic
ptimization of clinical pathways.
Whereas some studies have tried to develop and apply models to monitor the
edical outcomes with the aim to assess the internal clinical performance,1-4 there
s scant evidence in the thoracic surgery literature concerning the economic evalu-
tion of the postoperative course used as a quality indicator.5,6
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G
TSTherefore, the objectives of this study were to develop a
linically risk-adjusted model to estimate individual post-
perative costs after major lung resection and to use it to
rack the internal economic performance of our unit during
uccessive periods of activity.
atients and Methods
ariable and fixed hospital costs were individually and prospec-
ively collected for 679 consecutive patients submitted to major
ung resection (574 lobectomies and 105 pneumonectomies) from
anuary 2000 through October 2006 at our unit. This is a retro-
pective analysis performed on a prospectively compiled elec-
ronic database. The study was approved by the local institutional
eview board, and all patients gave their consent to use their data
n the dataset. As a rule, the operations were performed through a
uscle-sparing thoracotomy by the same surgical team (composed
f 4 certified staff general thoracic surgeons). Perioperative treat-
ent was standardized and focused on the control of postthora-
otomy chest pain, chest physiotherapy, early as possible mobili-
ation, and antibiotic and antithrombotic prophylaxis.
Major lung resections were contraindicated in those patients
ith a predicted postoperative forced expiratory volume in
second (ppoFEV1) and a predicted postoperative carbon mon-
xide lung diffusion capacity (ppoDLCO) less than 30% of pre-
icted, in addition to an insufficient exercise tolerance (height
eached at stair climbing test less than 12 m or a maximum volume
f oxygen utilization  10 mL · kg1 · min1).
Perioperative mortality in this series occurred in 27 (4%) pa-
ients who were included in the analysis.
Fixed and variable costs were retrieved from the data systems
f the Accounting and Pharmacy Departments of Umberto I Hos-
ital. For the purpose of this study, the costs were collected in
uros and converted in US dollars (conversion rate dollar/euro:
.285) and corrected according to the current inflation rate (as of
ovember 2006).
Fixed costs included capital, employee salaries, building main-
enance, and utilities. Variable costs included patient care supplies,
ood, radiographic film, laboratory reagents, medications with their
elivery systems (such as intravenous catheters or bottles), and the
ost of other postoperative therapeutic procedures such as cardio-
ersion, bronchoscopy, and blood transfusions.
Fixed costs derived from either service or support centers.
ervice centers were defined as those health care providers who
Abbreviations and Acronyms
PaCO2  arterial carbon dioxide level
PaO2  arterial oxygen tension
FEV1  forced expiratory volume in 1 second
FVC  forced vital capacity
ICU  intensive care unit
ppoDLCO predicted postoperative carbon monoxide
lung diffusion capacity
ppoFEV1  predicted postoperative forced expiratory
volume in 1 secondirectly care for patients such as physicians and nurses or depart- a
The Journal of Thoracicents that provide diagnostic or other measurable service to indi-
idual patients. Support center costs were of two types. The first
ype was nonsalary expenditures by the hospital for outside prod-
cts (eg, cleaning supplies, utilities, or health insurance benefits)
hat contribute to the function of the hospital and its employees.
he second type of support center cost was the salaries of employ-
es in departments such as housekeeping, payroll, and administra-
ion. They perform functions throughout the facility for the entire
rganization.
Our hospital is a public tertiary referral institution, in which all
mployees, including physicians, are salaried, warranting the cat-
gorization of salaries among the fixed costs.
The total fixed costs for medical services (such as thoracic ward
r intensive care unit [ICU]) include the salaries of employees
orking in the service centers providing the medical service plus
ll allocated support costs. So that the cost of medical services
ould be captured, all support center costs were allocated com-
letely to the service centers. For example, housekeeping costs
ere allocated to each service and support center on the basis of
ach center’s square footage. Likewise, payroll costs were allo-
ated to each service and support center relative to each center’s
otal number of full-time equivalent employees. Consequently, the
alculation of fixed costs for 1 day of stay in the thoracic ward and
n the ICU amounted to US $469 and US $1475.20, respectively.
All patients operated on during the period 2000 through 2003
364 lobectomy, 71 pneumonectomy) were used to develop the
isk-adjusted econometric model by a stepwise multiple regression
nalysis, which was subsequently validated by bootstrap analysis.
The following factors were used as independent variables in the
egression analysis (dependent variable: total individual postoper-
tive costs): age, arterial oxygen tension (PaO2), arterial carbon
ioxide level (PaCO2), smoking history (pack-years), preoperative
emoglobin concentration, serum albumin level, body mass index,
ype of operation (lobectomy vs pneumonectomy), presence of
oncomitant cardiac disease, diabetes, neoadjuvant chemotherapy,
reoperative pulmonary function tests (ratio of forced expiratory
olume in 1 second to forced vital capacity [FEV1/FVC ratio],
poFEV1, ppoDLCO, and ratio of residual volume to total lung
apacity), presence of concomitant cerebrovascular or symptom-
tic peripheral vascular diseases, presence of concomitant chronic
enal insufficiency, Eastern Cooperative Oncology Group/Zubrod
core, and Charlson Comorbidity index (see appendix for expla-
ation of variables).
All data were at least 95% complete. Sporadic missing data
ere imputed by averaging the nonmissing values (numerical
ariables) or taking the most frequent category (categorical vari-
bles). So that multicollinearity could be avoided, only one vari-
ble in a set of variables with a correlation coefficient greater than
.5 was selected (by bootstrap procedure) and used in the regres-
ion model.
A P value less than .05 was selected for retention of variables
n the final model. The multivariate procedure was then validated
y bootstrap bagging with 1000 samples. In the bootstrap proce-
ure, repeated samples of the same number of observations as the
riginal database were selected with replacement from the original
et observations. For each sample, stepwise multivariate regression
as performed. The stability of the final stepwise model can bessessed by identifying the variables that enter most frequently in
and Cardiovascular Surgery ● Volume 134, Number 3 625
t with
t pwis
m p
m dged
t
 op-
e , and
2 pre-
d ilk
n ared
w rank
t
per-
f  Inc,
C
R
T
(
m
s
p
r
o
(
. ing
m
1
c
t
t
t
o
i
e
e
p
$
v
r
l
$
p
t
2
F
a
T
s
V
A
D
B
F
D
E
C
P
C
P
N
R
s
D
O
T
y
o
V
I
A
C
p
S
w
e
General Thoracic Surgery Brunelli et al
6
G
TShe repeated bootstrap models and comparing those variables 
he variables in the final stepwise model. If the final ste
odel variables occur in a majority (50%) of the bootstra
odels, the original final stepwise regression model can be ju
o be stable.7-9
The model was then prospectively applied on all patients
rated on during the 3 subsequent periods (years 2004, 2005
006) to estimate the postoperative costs. Normality of the 
icted and observed costs was assessed by the Shapiro–W
ormality test. Observed and predicted costs were then comp
ithin each period by the Wilcoxon matched-pairs signed 
est.
All the statistical tests were 2-tailed. The analysis was 
ormed by the statistical softwares Statview 5.0 (SAS Institute,
ary, NC) and STATA 8.2 (Stata Corp, College Station, Tex).
esults
he characteristics of the patients in the derivation set
years 2000-2003) and of those operated on in the years
onitored by the econometric model (years 2004–2006) are
hown in Table 1.
Fixed costs accounted for 80% of the total observed
ostoperative costs.
Multiple regression analysis showed that significant and
eliable factors associated with postoperative costs were age
lder than 70 years (P  .05, bootstrap 51%), ppoFEV1
P .0001, bootstrap 100%), and cardiac comorbidity (P
005, bootstrap 92%) (Table 2). Consequently, the follow
odel predicting postoperative costs (US$) was derived:
ABLE 1. Characteristics of the patients in the derivation
et and in the periods under analysis
ariables
Derivation period
(2000–2003,
435 patients)
Periods under
analysis (2004–2006,
244 patients)
ge (y) 67 (9.3) 66.3 (10.8)
iagnosis (n, %)
Primary malignant 407 (93.6%) 227 (93%)
Metastatic 10 (2.3%) 7 (2.9%)
Infection 7 (1.6%) 6 (2.5%)
Benign, others 11 (2.5%) 4 (1.6%)
MI (kg/m2) 26.2 (4.3) 25.9 (3.8)
EV1 (%) 85.1 (19.1) 85.5 (18.5)
LCO (%) 76.2 (19.6) 79.6 (17.9)
COG score 0.98 (0.8) 0.7 (0.8)
CI 2 (1.7) 1.7 (1.6)
ack-years 40 (27.5) 44.1 (33.5)
ardiac disease (n, %) 212 (49%) 126 (52%)
neumonectomy (n, %) 71 (16%) 34 (14%)
eoadjuvant chemotherapy
(n, %)
67 (15%) 26 (11%)
esults are expressed as means  standard deviations unless otherwise
pecified. BMI, Body mass index; FEV1, forced expiratory volume in 1 second;oncology Group; CCI, Charlson Comorbidity index.
26 The Journal of Thoracic and Cardiovascular Surgery ● Septee
1,078  1340.3X (age  70 years)  1927.8X cardiac
omorbidity  95X ppoFEV1%.
The model showed satisfactory calibration in the deriva-
ion set after plotting the cumulative predicted costs against
he observed ones (Figure 1).
The econometric model was then prospectively applied
o predict individual postoperative costs in patients operated
n during the following 3 years. The results of the compar-
sons between observed and predicted postoperative costs in
ach of the 3 successive years of activity showed no differ-
nces between predicted and observed costs in the first 2
eriods analyzed (year 2004, $6188.40  $2180 vs
6241.40  $6884, P  .3; year 2005, $6308.60  $1971
s. $6483.60  $11,569, P  .4), whereas in the most
ecent period (year 2006), observed costs were significantly
ower than the predicted ones ($3457.30  $2079 vs
6162.70  $7748, P  .0001) with a mean saving per
atient of $2705.40.
Only 7.6% of patients in 2006 had observed costs higher
han 1 SD above the predicted costs, compared with 17% in
004 and 16% in 2005.
igure 1. Plot of the cumulative predicted postoperative costs
gainst the observed ones with the patients in the derivation set
ABLE 2. Results of the stepwise multiple regression anal-
sis (dependent variable: postoperative costs); parsimoni-
us model
ariables Coefficients SE P value Bootstrap %
ntercept 11,078 1,449
ge  70 y 1,340.3 686 .05 51%
ardiac disease 1,927.8 679 .005 92%
poFEV1 (%) 95 20 .0001 100%
E, Standard error; Bootstrap %, percentage of bootstrap samples in
hich the variable was significant (P  .05); ppoFEV1, predicted postop-
rative forced expiratory volume in 1 second.LCO, carbon monoxide lung diffusion capacity; ECOG, Eastern Cooperative
rdered by increasing predicted costs.
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G
TSTo rule out a possible effect of patient distributio
ostoperative costs, we assessed the distribution of ter
f predicted costs in each of the analyzed years (2004, 
nd 2006), finding no significant difference (2 1.9, P  .8).
Reduction of observed costs compared with that of 
icted costs in 2006 was mostly attributable to a shor
ospital stay and ICU stay. In fact, whereas in 200
edian hospital stay was 7 days (range 5– 40 days)
nly 11% of patients discharged before the sixth posto
tive day, and in 2005 the median stay was 7 days 
 –52 days) with 16% of patients discharged before the
ostoperative day, in 2006 the median stay was 6 
range 4 –16) and 42% of patients were discharged b
he sixth postoperative day. In 2006 we observed al
hortened mean ICU stay for those patients admitted
dvanced care management (2004, 7.4 days  4; 2005, 11.8
 11; 2006, 4  3.2) with no mortality in the ICU. The
f blood transfusion was also reduced in 2006 and con
ted to the reduction of observed costs (mean blood units
er patient: 2004, 1.8 units; 2005, 1.4 units; 2006, 0.6 units).
iscussion
he most basic tenet of any industrial process is a clear
ssessment of operating costs. This is necessary to judge
utcome (profits) and to implement cost-effective strategies.
ospitals in particular, and health care providers in general,
ave been remiss in avoiding this concept that industry uses
s a fundamental starting point for successful outcome.
ccurate cost data are the single most important piece of
nformation almost uniformly lacking in hospital adminis-
ration today.
Optimization and quality assurance of medical interven-
ions have become an important part of our clinical practice,
wing to the relative scarcity of resources.
Risk modeling is an essential element in quality moni-
oring and improving processes and has been used for
nternal and external evaluation of performance through the
ssessment of traditional outcome measures such as mor-
idity and mortality.1-4 On the other hand, cost-based ec-
omic evaluation of thoracic surgical care has rarely been
aken into consideration as a possible performance indica-
or.5,6 Indeed, predicting individual costs in a population
urgical patients and tracking the agreement between pre-
icted and observed costs during different periods of activ-
ty may be of great importance in optimizing pathways of
are and for a more accurate allocation of resources.
Although no statistical risk model can replace clinical
udgment, good decision-making must begin with good
nformation. In this regard, greater precision in predicting
utcome and costs after therapy may provide clinicians with
eference points to augment decision-making by increasing
he level of information and communication.10 t
The Journal of Thoracic,
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Therefore, this study aimed to develop a clinically risk-
djusted model to estimate individual postoperative costs
fter major lung resection and to use it to track the internal
conomic performance of our unit during successive periods
f activity. The main intent was not to develop an econo-
etric model that could be generalized to other settings but
o prove that economic parameters can be risk-modeled by
sing clinical data and that risk-adjusted econometric anal-
sis can be used to evaluate the quality of our practice in
ddition to other more common outcome indicators (such as
orbidity and mortality).
The most relevant characteristics of this study are that we
sed clinical factors and not administrative variable to risk-
djust the economic data and that the model is based on true
ndividual costs and not on charge-based accounting.
Although administrative data provide one of the most
sed sources for observational studies, because they are
eadily available and relatively inexpensive11,12 they have
een collected primarily for billing purposes rather than for
linical studies, and critical variables such as ppoFEV1 or
poDLCO may be unavailable. In addition, differentiation
f comorbidities from complications may be problematic.
dministrative databases may limit the number of second-
ry diagnoses and generally have poor flexibility to properly
lassify certain comorbidities.12 For all these reason
laims data should be avoided whenever possible if the aim
f the analysis is to assess the clinical performance of the
rovider.
The gold standard for data should be a specialty-specific,
rocedure-specific, prospectively maintained, periodically
udited electronic clinical database.4
Relative comparisons with charge-based accounting may
e useful as a first approximation, but interventions aimed at
ost saving should be based on true cost-accounting meth-
ds. This is particularly true because charges are changing
t a rapid rate and are basically mandated without much
oncern for true costs.
Our model was developed from a set of patients operated
n during an earlier period (2000–2003) with respect to
hose in whom we assessed the economic performance
2004–2006). This represents an example of temporal qual-
ty benchmark. The model was generated by multiple re-
ression analysis and validated by bootstrap procedure by
sing the entire dataset (2000–2003), without resorting to
he traditional training and test method. In fact, we and
thers have shown that bootstrap is superior to the training
nd test splitting of the dataset, inasmuch as more reliable
nd reproducible predictive equations are generated.7,9
When the model was then prospectively applied to com-
are the observed and predicted postoperative costs, we
ound that, whereas during the years 2004 and 2005 the
bserved costs were in line with the predicted ones, in 2006
he observed costs were significantly lower than expected.
and Cardiovascular Surgery ● Volume 134, Number 3 627
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TShe mean saving per patient with respect to the pred
osts amounted to US $2705, with a savings in the
opulation of patients of approximately US $181,282. 
xpected by the distribution of fixed versus variable c
hich was in agreement with previous investigations 
ormed in other settings,13 most of the savings were attr-
table to reduced fixed costs by a shortening of posto
ive hospital stay and a reduction in ICU stay for 
atients admitted to the ICU. These improvements in p
perative management care are the results of a fast-trac
olicy that was instituted in 2006 for major lung resec
oreover, as of January 2006, maximum volume of ox
tilization measurement was added in the preoperat
orkup of all lung resection candidates, which allowe
ore accurate selection of patients that could be sa
ast-tracked.
If they are to be reliably used as performance indic
osts should always complement traditional clinical o
ome indicators. In fact, after clinical risk-adjustment, c
an represent a measure against which morbidity and 
ality could be weighed on a level playing field.
In this regard, we did not find any differences bet
bserved and predicted (by using previously valida
odels4 ) morbidity and mortality within each of 
eriods of activity. This confirmed that the reduction
ostoperative costs was achieved without compromisi
he clinical outcomes and was the result of the instit
f a fast-track policy in patients treated with major 
esections.
We showed that a clinically risk-adjusted econome
odel was able to detect a successful cost-containm
olicy. For this reason, we think it may represent a com
nstrument that can be used both by the administrators
y the clinicians for performance evaluation and budge
easons.
A reduction in the observed costs does not automati
ranslate into improved efficiency unless corrective m
ures based on the reduction of resources caring for
atients or on the increase of operations performed 
pplied. We anticipate that, should our results be confir
uring the next year, corrective measures on resources
ization will be elaborated and discussed during ann
udget negotiations. The most important result of this s
as that we were able to provide clinicians and admin
ors with a reliable instrument for monitoring the costs 
ajor lung resections so that they could adopt approp
easures to improve clinical cost-effectiveness. In our p
ice, the number of operations is dependent either on
umber of referrals or on the availability of postoper
eds and personnel that limit to cycle more patients i
erioperative setting. In this context, a reliable econome
nstrument may allow a more accurate allocation of
ources to improve efficiency.
28 The Journal of Thoracic and Cardiovascular Surgery ● Septel
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In fact, potential applications of econometric risk-model
ay include reinvestment of potentially saved economic
ources to further implement quality-improving strategies, 
ropriate allocation of resources during annual budget dis
ion, and negotiation of prospective charges with finan
nstitutions.
This analysis may have potential limitations. First, o
ostoperative costs were assessed. Preoperative worku
ntraoperative, and primary care postoperative costs w
ot the objects of this study. Therefore, our work cann
nterpreted as an assessment of the total expenditure o
ealth care system for a lung resection patient.
Second, our hospital has a high patient volume, allow
conomies of scale. We negotiate low rates for consuma
y large volume purchasing. Moreover, our public hosp
orks with a restricted budget. Expenditures for supp
uch as pharmaceuticals are kept as low as possible. 
icians are expected to order medications available on
ormulary and more expensive patent medications are 
hased only if clear benefit or special need is demonstr
his may partly explain the low proportion of variable c
hich may not be reproducible at other settings.
As for other more traditional indicators of performa
ven this economic model was intended for quality purp
nly and not for patient selection, a process that should be
ased on clinical judgment and not on statistical models1,3,4
In conclusion, we as physicians should assume complete
esponsibility in selecting the evaluation instruments and
nd points, not only for evaluating our clinical performance
ut even for the economic assessment of our practice.
Although the costs are hospital- and system-specific, our
conomic model may serve as a methodologic template for
linical cost analysis in our specialty and may complement
ther more traditional outcome measures (ie, morbidity and
ortality) in the performance monitoring process.
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ppendix
he following variables were tested for a possible association with
ostoperative costs: age, PaO2, arterial carbon dioxide level
PaCO2), smoking history (pack-years), preoperative hemoglobin
oncentration, serum albumin level, body mass index, type of
peration (lobectomy vs pneumonectomy), presence of concomi-
ant cardiac disease, diabetes, neoadjuvant chemotherapy, preop-
rative pulmonary function tests (FEV /FVC ratio, ppoFEV ,1 1
poDLCO, ratio of residual volume to total lung capacity), pres- w
The Journal of Thoracicnce of concomitant cerebrovascular or symptomatic peripheral
ascular diseases, and presence of concomitant chronic renal in-
ufficiency.
We computed the number of pack-years of smoking as the total
umber of years smoked multiplied by the average number of
igarettes smoked per day, divided by 20.
Pulmonary function tests were performed according to the
merican Thoracic Society criteria. Results of spirometry were
ollected after bronchodilator administration. DLCO was mea-
ured by the single breath method.
The ppoFEV1 and ppoDLCO were expressed as percentages of
redicted for age, sex, and height and were calculated by estimat-
ng the amount of functioning parenchyma removed during the
perations by bronchoscopy, computed tomographic scan, and
uantitative lung perfusion scan.
For the purpose of the present study and in accordance with
revious investigations,2-4 a concomitant cardiac disease was de-
ned as follows: previous cardiac surgery, previous myocardial
nfarction, history of coronary artery disease, and current treatment
or arrhythmia, cardiac failure, or hypertension. We chose to use
his definition of cardiac comorbidity for the sake of compari-
on with previous studies and for numerical reasons. In fact,
reaking down the variable in the single cardiac diseases would
ave resulted in too many cofactors with limited representation.
lthough not weighed, all cardiac conditions included in the
ariable are widely recognized cardiac risk factors for noncar-
iac surgery.
Eastern Cooperative Oncology Group score was calculated
ccording to Oken and associates.14 Charlson Comorbidity index
as calculated according to Birim and associates.15
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